Literature DB >> 14974857

Intratympanic gentamicin for intractable Meniere's disease: 5-year follow-up.

Jason Atlas1, Lorne S Parnes.   

Abstract

OBJECTIVE: To determine the efficacy and morbidity of intratympanic gentamicin titration therapy on patients with incapacitating unilateral Meniere's disease.
METHOD: The study consisted of a retrospective chart review and patient interviews. Sixty-eight patients had been followed for a minimum of 24 months and were reported on in an earlier study. Forty-six of these individuals were available for detailed follow-up at 5 years post-gentamicin therapy. MAIN OUTCOME MEASURES: Vertigo frequency, hearing status, personal disability ratings, and tinnitus level before and after gentamicin therapy were measured.
RESULTS: Seventy-four percent of patients showed complete vertigo control and an additional 7% showed substantial vertigo control. There was also significant improvement in personal ratings of social and economic functioning. Overall, the group showed no combined statistically significant changes in any of the hearing parameters.
CONCLUSION: Intratympanic gentamicin titration therapy provides excellent vertigo control, with a similarly significant improvement in both personal and occupational functioning.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14974857     DOI: 10.2310/7070.2003.11249

Source DB:  PubMed          Journal:  J Otolaryngol        ISSN: 0381-6605


  3 in total

1.  Is surgical vestibular ablation necessary in disabling peripheral vertigo?

Authors:  A Mahadevaiah; Bhavin Parikh
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2008-04-03

2.  Intratympanic (IT) Therapies for Menière's Disease: Some Consensus Among the Confusion.

Authors:  Desi P Schoo; Grace X Tan; Matthew R Ehrenburg; Seth E Pross; Bryan K Ward; John P Carey
Journal:  Curr Otorhinolaryngol Rep       Date:  2017-05-03

3.  Intratympanic gentamicin treatment for Ménière's disease: a randomized, double-blind, placebo-controlled trial on dose efficacy - results of a prematurely ended study.

Authors:  Hendrik G Bremer; Ingrid van Rooy; Bas Pullens; Carla Colijn; Inge Stegeman; Hester J van der Zaag-Loonen; Peter Paul van Benthem; Sjaak F L Klis; Wilko Grolman; Tjasse D Bruintjes
Journal:  Trials       Date:  2014-08-18       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.